|
Index | - | P/E | - | EPS (ttm) | -1.08 | Insider Own | - | Shs Outstand | 5.68M | Perf Week | 0.73% |
Market Cap | 15.62M | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 4.56M | Perf Month | -10.71% |
Income | - | PEG | - | EPS next Q | - | Inst Own | 2.69% | Short Float | 0.05% | Perf Quarter | -4.84% |
Sales | 0.36M | P/S | 43.83 | EPS this Y | - | Inst Trans | - | Short Ratio | 0.22 | Perf Half Y | -16.67% |
Book/sh | 4.56 | P/B | 0.60 | EPS next Y | - | ROA | - | Target Price | - | Perf Year | -59.38% |
Cash/sh | - | P/C | - | EPS next 5Y | - | ROE | - | 52W Range | 2.32 - 5.20 | Perf YTD | 10.00% |
Dividend | - | P/FCF | - | EPS past 5Y | - | ROI | - | 52W High | -47.12% | Beta | - |
Dividend % | - | Quick Ratio | - | Sales past 5Y | - | Gross Margin | - | 52W Low | 18.53% | ATR | 0.19 |
Employees | - | Current Ratio | - | Sales Q/Q | 1037.30% | Oper. Margin | - | RSI (14) | 44.79 | Volatility | 4.98% 6.88% |
Optionable | No | Debt/Eq | - | EPS Q/Q | - | Profit Margin | - | Rel Volume | 0.16 | Prev Close | 2.74 |
Shortable | Yes | LT Debt/Eq | - | Earnings | - | Payout | - | Avg Volume | 9.93K | Price | 2.75 |
Recom | 2.00 | SMA20 | -3.57% | SMA50 | -8.99% | SMA200 | -22.79% | Volume | 1,549 | Change | 0.36% |
![]() |
|
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Immuron Limited, a biopharmaceutical company, researches, develops, and commercializes polyclonal antibodies in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It markets Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and reduce the symptoms of minor gastro-intestinal disorders, as well as for dietary supplement for digestive tract protection; and Protectyn, an immune supplement to maintain a healthy digestive function and liver. The company is also developing Travelan (IMM-124E) that is in Phase III clinical trials to reduce the risk of contracting travelers' diarrhea, as well as acts as an anti-viral activity against SARS-CoV-2; and IMM-529, which is in clinical development stage focuses on treating patients suffering from recurring clostridium difficile infection. It has a research agreement with Naval Medical Research Center to develop and clinically evaluate a therapeutic targeting Campylobacter and ETEC infections; and a collaboration agreement with the Walter Reed Army Institute of Research to develop an oral therapeutic for shigellosis. Immuron Limited was incorporated in 1994 and is based in Carlton, Australia. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() |
open in yahoo | open in reuters | open in marketwatch | open in google |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite